Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Recombinant DNA01:09

Recombinant DNA

Overview
Transgenic Organisms00:53

Transgenic Organisms

Overview
Transgenic Organisms00:53

Transgenic Organisms

Overview
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source.

mBio·2024
Same author

No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model.

PloS one·2024
Same author

A fully human monoclonal antibody possesses antibody-dependent cellular cytotoxicity (ADCC) activity against the H1 subtype of influenza A virus by targeting a conserved epitope at the HA1 protomer interface.

Journal of medical virology·2023
Same author

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague.

Antibodies (Basel, Switzerland)·2023
Same author

Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019.

The Journal of infectious diseases·2022
Same author

Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants.

Human vaccines & immunotherapeutics·2021

Related Experiment Video

Updated: Jul 8, 2026

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood

Published on: January 6, 2022

Commercialising genetically engineered animal biomedical products.

Eddie J Sullivan1, Jerry Pommer, James M Robl

  • 1Hematech Inc., 4401 S. Technology Dr., Sioux Falls, SD 57106, USA. esullivan@hematech.com

Reproduction, Fertility, and Development
|December 25, 2007
PubMed
Summary

Developing biomedical products from genetically engineered animals faces significant challenges. Researchers must navigate complex steps from research to commercialization, balancing risks and public benefits.

More Related Videos

Generation of a Bovine Primary Enteroid-Derived Two-Dimensional Monolayer Culture System for Applications in Translational Biomedical Research
07:56

Generation of a Bovine Primary Enteroid-Derived Two-Dimensional Monolayer Culture System for Applications in Translational Biomedical Research

Published on: April 5, 2024

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Related Experiment Videos

Last Updated: Jul 8, 2026

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood

Published on: January 6, 2022

Generation of a Bovine Primary Enteroid-Derived Two-Dimensional Monolayer Culture System for Applications in Translational Biomedical Research
07:56

Generation of a Bovine Primary Enteroid-Derived Two-Dimensional Monolayer Culture System for Applications in Translational Biomedical Research

Published on: April 5, 2024

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Area of Science:

  • Biotechnology
  • Animal Genetics
  • Biomedical Engineering

Background:

  • Technological advancements have improved the creation of genetically engineered animals.
  • The pipeline for biomedical products derived from these animals is expanding.
  • Transitioning from research to commercialization presents substantial hurdles.

Purpose of the Study:

  • To outline the multifaceted challenges in developing and commercializing biomedical products from genetically engineered animals.
  • To provide researchers with a realistic understanding of the development pathway.
  • To inform risk-benefit analyses for novel applications.

Main Methods:

  • Review of current tools and processes for genetic engineering in animals.
  • Analysis of key stages in product development, including quality control, risk management, and facility requirements.
  • Examination of successful and developing applications in the field.

Main Results:

  • Numerous complex and costly steps are required for early-stage development.
  • These include establishing founder animals, cell banking, and specialized facilities.
  • Despite successes, commercialization requires careful planning and resource allocation.

Conclusions:

  • Developing genetically engineered animal applications requires a comprehensive understanding of the entire process.
  • Researchers must consider logistical, financial, and regulatory complexities.
  • Realistic assessment is crucial for determining the viability and potential impact of these innovations.